Search Results

There are 8333 results for: content related to: QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone

  1. Oral paliperidone for schizophrenia

    Intervention Review

    The Cochrane Library

    Abraham M Nussbaum and T S Stroup

    Published Online : 23 APR 2008, DOI: 10.1002/14651858.CD006369.pub2

  2. Paliperidone palmitate for schizophrenia

    Intervention Review

    The Cochrane Library

    Abraham M Nussbaum and T S Stroup

    Published Online : 13 JUN 2012, DOI: 10.1002/14651858.CD008296.pub2

  3. You have free access to this content
    Signalling profile differences: paliperidone versus risperidone

    British Journal of Pharmacology

    Volume 170, Issue 3, October 2013, Pages: 532–545, W P Clarke, T A Chavera, M Silva, L C Sullivan and K A Berg

    Article first published online : 17 SEP 2013, DOI: 10.1111/bph.12295

  4. Paliperidone Extended-Release for the Treatment of Schizophrenia

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 28, Issue 10, October 2008, Pages: 1283–1298, Jehan Marino and Joshua Caballero

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.28.10.1283

  5. You have free access to this content
    Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication

    International Journal of Clinical Practice

    Volume 64, Issue 2, January 2010, Pages: 216–239, L. Citrome

    Article first published online : 3 NOV 2009, DOI: 10.1111/j.1742-1241.2009.02240.x

  6. Risperidone and Paliperidone in the Treatment of Bipolar Disorder

    Bipolar Psychopharmacotherapy: Caring for the Patient, Second Edition

    L. Ivo Caers, Joris Berwaerts, Pages: 153–192, 2011

    Published Online : 13 APR 2011, DOI: 10.1002/9780470975114.ch9

  7. Risperidone (depot) for schizophrenia

    Intervention Review

    The Cochrane Library

    Stephanie Sampson, Prakash Hosalli, Vivek A Furtado and John M Davis

    Published Online : 14 APR 2016, DOI: 10.1002/14651858.CD004161.pub2

  8. You have free access to this content
    Paliperidone: quo vadis?

    International Journal of Clinical Practice

    Volume 61, Issue 4, April 2007, Pages: 653–662, L. Citrome

    Article first published online : 2 MAR 2007, DOI: 10.1111/j.1742-1241.2007.01321.x

  9. You have free access to this content
    Quetiapine versus other atypical antipsychotics for schizophrenia

    Intervention Review

    The Cochrane Library

    Laila Asmal, Srnka J Flegar, Jikun Wang, Christine Rummel-Kluge, Katja Komossa and Stefan Leucht

    Published Online : 18 NOV 2013, DOI: 10.1002/14651858.CD006625.pub3

  10. You have free access to this content
    Studies on the Acute Toxicity, Pharmacokinetics and Pharmacodynamics of Paliperidone Derivatives – Comparison to Paliperidone and Risperidone in Mice and Rats

    Basic & Clinical Pharmacology & Toxicology

    Volume 107, Issue 2, August 2010, Pages: 656–662, Fengying Sun, Zhengxing Su, Cheng Sui, Chao Zhang, Lijia Yuan, Qingfan Meng, Lirong Teng and Youxin Li

    Article first published online : 25 MAR 2010, DOI: 10.1111/j.1742-7843.2010.00552.x

  11. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder

    Bipolar Disorders

    Volume 12, Issue 3, May 2010, Pages: 230–243, Eduard Vieta, Isaac F Nuamah, Pilar Lim, Eric C Yuen, Joseph M Palumbo, David W Hough and Joris Berwaerts

    Article first published online : 10 MAY 2010, DOI: 10.1111/j.1399-5618.2010.00815.x

  12. Single- and Multiple-Dose Pharmacokinetics and Dose Proportionality of the Psychotropic Agent Paliperidone Extended Release

    The Journal of Clinical Pharmacology

    Volume 49, Issue 11, November 2009, Pages: 1318–1330, Dr Sandra Boom, Dr Krishna Talluri, Mr Luc Janssens, Dr Bart Remmerie, Dr Marc De Meulder, Dr Stefaan Rossenu, Dr Nancy van Osselaer, Dr Marielle Eerdekens and Dr Adriaan Cleton

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009339190

  13. Use of high-conductivity sample solution with sweeping-micellar electrokinetic capillary chromatography for trace-level quantification of paliperidone in human plasma

    ELECTROPHORESIS

    Volume 36, Issue 4, February 2015, Pages: 534–542, Hsiang-Yin Liu, Tzung-Jeng Hwang, I-Lin Tsai and Ching-Hua Kuo

    Article first published online : 22 JAN 2015, DOI: 10.1002/elps.201400230

  14. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone

    The Journal of Clinical Pharmacology

    Volume 55, Issue 1, January 2015, Pages: 93–103, Celine M. Laffont, Roberto Gomeni, Bo Zheng, Christian Heidbreder, Paul J. Fudala and Azmi F. Nasser

    Article first published online : 23 JUL 2014, DOI: 10.1002/jcph.366

  15. Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers

    Human Psychopharmacology: Clinical and Experimental

    Volume 27, Issue 3, May 2012, Pages: 305–314, Kil-Sang Yoon, Tae-Won Park, Jong-Chul Yang, Min-Gul Kim, Keun-Young Oh, Myung-Sook Park and Young-Chul Chung

    Article first published online : 15 MAY 2012, DOI: 10.1002/hup.2227

  16. Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial

    Acta Neuropsychiatrica

    Volume 23, Issue 4, August 2011, Pages: 179–183, Ho-Kyoung Yoon, Yong-Ku Kim, Changsu Han, Young-Hoon Ko, Heon-Jeong Lee, Do-Young Kwon and Leen Kim

    Article first published online : 23 MAY 2011, DOI: 10.1111/j.1601-5215.2011.00568.x

  17. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia

    Journal of Psychiatric and Mental Health Nursing

    Volume 15, Issue 10, December 2008, Pages: 792–799, A. JONES

    Article first published online : 4 NOV 2008, DOI: 10.1111/j.1365-2850.2008.01299.x

  18. Modeling the Effectiveness of Paliperidone ER and Olanzapine in Schizophrenia: Meta-Analysis of 3 Randomized, Controlled Clinical Trials

    The Journal of Clinical Pharmacology

    Volume 50, Issue 3, March 2010, Pages: 293–310, Ignacio Ortega, Juan Jose Perez-Ruixo, Kim Stuyckens, Vladimir Piotrovsky and An Vermeulen

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009346057

  19. Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5

    Human Psychopharmacology: Clinical and Experimental

    Volume 31, Issue 2, March 2016, Pages: 93–102, Maho Okubo, Shoko Morita, Norie Murayama, Youichi Akimoto, Akiko Goto and Hiroshi Yamazaki

    Article first published online : 8 FEB 2016, DOI: 10.1002/hup.2516

  20. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia

    Clinical Pharmacology in Drug Development

    Volume 4, Issue 4, July/August 2015, Pages: 270–278, Stefaan Rossenu, Adriaan Cleton, David Hough, Herta Crauwels, An Vandebosch, Joris Berwaerts, Marielle Eerdekens, Virginie Herben, Marc De Meulder, Bart Remmerie and Igor Francetic

    Article first published online : 27 AUG 2014, DOI: 10.1002/cpdd.144